Billiontoone (NASDAQ:BLLN) Stock Rating Lowered by Wall Street Zen

Billiontoone (NASDAQ:BLLN) was downgraded by analysts at Wall Street Zen from a “buy” rating to a “hold” rating in a report issued on Saturday.

BLLN has been the subject of several other research reports. JPMorgan Chase & Co. cut their target price on Billiontoone from $145.00 to $130.00 and set an “overweight” rating for the company in a research report on Thursday. Weiss Ratings upgraded Billiontoone from a “sell (d)” rating to a “sell (d+)” rating in a research note on Tuesday, June 23rd. Guggenheim initiated coverage on Billiontoone in a report on Monday, June 29th. They set a “buy” rating and a $125.00 price objective for the company. Finally, BTIG Research reduced their target price on shares of Billiontoone from $142.00 to $130.00 and set a “buy” rating on the stock in a research note on Thursday. Six research analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, Billiontoone has an average rating of “Moderate Buy” and a consensus price target of $126.71.

Billiontoone Stock Performance

NASDAQ:BLLN opened at $93.39 on Friday. Billiontoone has a 12-month low of $61.96 and a 12-month high of $150.44. The company has a quick ratio of 11.31, a current ratio of 11.69 and a debt-to-equity ratio of 0.17. The firm has a market capitalization of $4.30 billion and a PE ratio of 133.41. The firm has a 50-day moving average price of $116.49 and a 200 day moving average price of $94.31.

Billiontoone (NASDAQ:BLLN) last released its quarterly earnings data on Wednesday, August 5th. The company reported $0.15 earnings per share for the quarter, meeting analysts’ consensus estimates of $0.15. Billiontoone had a return on equity of 9.96% and a net margin of 8.04%.The company had revenue of $109.45 million for the quarter. Research analysts anticipate that Billiontoone will post 0.92 earnings per share for the current fiscal year.

Insider Activity at Billiontoone

In other news, CEO Oguzhan Atay sold 32,500 shares of the company’s stock in a transaction that occurred on Monday, August 3rd. The shares were sold at an average price of $136.95, for a total transaction of $4,450,875.00. Following the transaction, the chief executive officer directly owned 20,000 shares in the company, valued at approximately $2,739,000. This represents a 61.90% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Shan Riku Sakakibara sold 4,000 shares of the stock in a transaction that occurred on Friday, July 31st. The shares were sold at an average price of $140.21, for a total transaction of $560,840.00. Following the sale, the insider directly owned 200,000 shares in the company, valued at $28,042,000. This trade represents a 1.96% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last 90 days, insiders have sold 202,049 shares of company stock worth $23,496,861. 50.22% of the stock is owned by insiders.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the stock. Rossby Financial LCC bought a new position in Billiontoone in the 4th quarter valued at $25,000. Wells Fargo & Company MN acquired a new stake in shares of Billiontoone in the 4th quarter valued at $76,000. Smartleaf Asset Management LLC bought a new stake in shares of Billiontoone during the fourth quarter worth $80,000. Nano Cap New Millennium Growth Fund L P acquired a new position in shares of Billiontoone during the fourth quarter valued at $82,000. Finally, Renaissance Capital LLC acquired a new position in shares of Billiontoone during the fourth quarter valued at $201,000.

About Billiontoone

BillionToOne (NASDAQ: BLLN) is a molecular diagnostics company that develops and commercializes high-precision genetic testing solutions based on single-molecule counting technology. The company’s platform is designed to detect and quantify rare genetic variants and chromosomal abnormalities from cell-free DNA, with a primary focus on applications in prenatal screening and other clinical genetic tests where sensitivity and specificity at very low allele fractions are critical.

BillionToOne’s offerings center on assay development and clinical testing workflows that enable non-invasive prenatal testing (NIPT) and targeted molecular diagnostics.